These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 30827472

  • 1. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
    Moon SM, Choe J, Jhun BW, Jeon K, Kwon OJ, Huh HJ, Lee NY, Daley CL, Koh WJ.
    Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
    [Abstract] [Full Text] [Related]

  • 2. [Fever and thin-walled cavitary lung lesions].
    Ramos A, Daza R, Alvarez-Espejo T, Guzmán MF.
    Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):363-4. PubMed ID: 19419797
    [No Abstract] [Full Text] [Related]

  • 3. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.
    Santin M, Dorca J, Alcaide F, Gonzalez L, Casas S, Lopez M, Guerra MR.
    Eur Respir J; 2009 Jan; 33(1):148-52. PubMed ID: 19118226
    [Abstract] [Full Text] [Related]

  • 4. Clinical and epidemiological characteristics of M. kansasii pulmonary infections from Rio de Janeiro, Brazil, between 2006 and 2016.
    Goldenberg T, Gayoso R, Mogami R, Lourenço MC, Ramos JP, Carvalho LD, Dalcolmo MP, Mello FCQ.
    J Bras Pneumol; 2020 Jan; 46(6):e20190345. PubMed ID: 32696934
    [Abstract] [Full Text] [Related]

  • 5. Temporal interferon-gamma release response to Mycobacterium kansasii infection in an anorexia nervosa patient.
    Cosson MA, Bertrand JB, Martin C, Veziris N, Picard C, Goulvestre C, Coignard S, Benoit JP, Silvera S, Moro MR, Poyart C, Morand PC.
    J Med Microbiol; 2012 Nov; 61(Pt 11):1617-1620. PubMed ID: 22859583
    [Abstract] [Full Text] [Related]

  • 6. Mycobacterium kansasii pulmonary diseases in Korea.
    Yim JJ, Park YK, Lew WJ, Bai GH, Han SK, Shim YS.
    J Korean Med Sci; 2005 Dec; 20(6):957-60. PubMed ID: 16361804
    [Abstract] [Full Text] [Related]

  • 7. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
    Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
    [Abstract] [Full Text] [Related]

  • 8. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
    Jeong BH, Jeon K, Park HY, Kim SY, Lee KS, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ.
    Am J Respir Crit Care Med; 2015 Jan 01; 191(1):96-103. PubMed ID: 25393520
    [Abstract] [Full Text] [Related]

  • 9. Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial.
    Zweijpfenning SMH, Aarnoutse R, Boeree MJ, Magis-Escurra C, Stemkens R, Geurts B, van Ingen J, Hoefsloot W.
    Chest; 2024 May 01; 165(5):1082-1092. PubMed ID: 38040054
    [Abstract] [Full Text] [Related]

  • 10. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.
    Zweijpfenning S, Kops S, Magis-Escurra C, Boeree MJ, van Ingen J, Hoefsloot W.
    Respir Med; 2017 Oct 01; 131():220-224. PubMed ID: 28947034
    [Abstract] [Full Text] [Related]

  • 11. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii.
    Ahn CH, Lowell JR, Ahn SS, Ahn SI, Hurst GA.
    Am Rev Respir Dis; 1983 Dec 01; 128(6):1048-50. PubMed ID: 6650978
    [Abstract] [Full Text] [Related]

  • 12. Rifampin-resistant Mycobacterium kansasii.
    Wallace RJ, Dunbar D, Brown BA, Onyi G, Dunlap R, Ahn CH, Murphy DT.
    Clin Infect Dis; 1994 May 01; 18(5):736-43. PubMed ID: 8075262
    [Abstract] [Full Text] [Related]

  • 13. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea.
    Park HK, Koh WJ, Shim TS, Kwon OJ.
    Yonsei Med J; 2010 Jul 01; 51(4):552-6. PubMed ID: 20499421
    [Abstract] [Full Text] [Related]

  • 14. [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].
    Wagner D, Lange C.
    Dtsch Med Wochenschr; 2020 Aug 01; 145(16):1145-1151. PubMed ID: 32791550
    [Abstract] [Full Text] [Related]

  • 15. [Nontuberculous Mycobacterial Pulmonary Disease - The New ATS/ERS/ESCMID/IDSA Guideline].
    Wagner D, Lange C.
    Pneumologie; 2020 Nov 01; 74(11):773-779. PubMed ID: 33202438
    [Abstract] [Full Text] [Related]

  • 16. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy.
    Sauret J, Hernández-Flix S, Castro E, Hernández L, Ausina V, Coll P.
    Tuber Lung Dis; 1995 Apr 01; 76(2):104-8. PubMed ID: 7780090
    [Abstract] [Full Text] [Related]

  • 17. Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.
    Srivastava S, Boorgula GD, Wang JY, Huang HL, Howe D, Gumbo T, Heysell SK.
    Antimicrob Agents Chemother; 2022 Apr 19; 66(4):e0232021. PubMed ID: 35315686
    [Abstract] [Full Text] [Related]

  • 18. [Nontuberculous mycobacterial infections of the lung].
    Latshang TD, Lo Cascio CM, Russi EW.
    Ther Umsch; 2011 Jul 19; 68(7):402-6. PubMed ID: 21728159
    [Abstract] [Full Text] [Related]

  • 19. Clinical and radiological features of Mycobacterium kansasii and other NTM infections.
    Matveychuk A, Fuks L, Priess R, Hahim I, Shitrit D.
    Respir Med; 2012 Oct 19; 106(10):1472-7. PubMed ID: 22850110
    [Abstract] [Full Text] [Related]

  • 20. [THE GENETIC EXAMINATION OF BRONCHIAL LAVAGE ENABLES THE PROMPT DIAGNOSIS OF PULMONARY MYCOBACTERIUM KANSASII--A CASE REPORT].
    Mori M, Ageshio F, Kagawa H, Oshitani Y, Fujikawa T, Saito H, Sako H, Yano Y, Kitada S, Maekura R.
    Kekkaku; 2015 Aug 19; 90(8):619-23. PubMed ID: 26665518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.